Einsatz der Radiosynoviorthese (RSO) an Fuß und Sprunggelenk: Indikation, Durchführung, Ergebnisse und Grenzen

Abstract Background Radiosynoviorthesis (RSO) is a tried and tested, less invasive nuclear medicine therapy for inflammatory joint diseases as well as pigmented villonodular synovitis after previous surgical synovectomy and joint involvement in hemophilia. The RSO is the most common outpatient radionuclide therapy in Germany. Methods The RSO method is presented as well as an explanation of the results, limits and potential risks based on the current literature. The pre-therapeutic diagnostics, the preparation and implementation of the RSO as well as the follow-up care after RSO are presented. Results The aim of the RSO is to treat the affected synovial membrane with locally effective radiation to prevent progression. In up to > 80% of the treated patients, there is a significant reduction in inflammatory changes and effusion or pain symptoms and thus an improvement in joint function after a RSO. The response rate depends, among other things, on the extent to which the radiocolloids are stored in the synovial membrane. New studies show a significantly longer therapeutic efficiency compared to intra-articular corticosteroid application after RSO. Conclusions The RSO is a well established, safe treatment option with only few side effects, especially for patients with synovitis. The indication for RSO and follow-up care should be carried out in close cooperation between the nuclear medicine specialist and the referring physician.